NewsBenzingaTeva Pharmaceutical Indus eleva la guía de BPA ajustado para el ejercicio 2026 de $1.91-$2.11 a $1.92-$2.11, frente a una estimación de $1.98; eleva la guía de ventas para el ejercicio 2026 de $16.500B-$16.850B a $16.700B-$17.000B, frente a una... Teva Pharmaceutical Indus eleva la guía de BPA ajustado para el ejercicio 2026 de $1.91-$2.11 a $1.92-$2.11, frente a una estimación de $1.98; eleva la guía de ventas para el ejercicio 2026 de $16.500B-$16.850B a $16.700B-$17.000B, frente a una... Benzinga 2026.11.03 12:08 (GMT+0) Open on Benzinga Other news AI models can be tricked into identifying civilians as military targets by telling them it’s a game Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies McKesson Stock Is a Triple Threat at New All-Time Highs. How to Trade It Here. 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT